Curated News
By: NewsRamp Editorial Staff
December 04, 2024

Glycyx Sheds Light on Opioid-Induced Immunotherapy Failure in Cancer Treatment

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • Glycyx advances axelopran to address opioid-induced immunotherapy failure, gaining IND status for clinical trials.
  • Axelopran, a mu-opioid receptor antagonist, targets immunosuppression to enhance immune checkpoint inhibitors for cancer treatment.
  • Glycyx's research on opioid effects in cancer treatment aims to improve outcomes, supporting better immunotherapy options for patients.
  • Publication in JITC highlights critical findings on opioids and immunotherapy, paving the way for innovative cancer treatment strategies.

Impact - Why it Matters

This news matters as it underscores the critical need to address the impact of opioids on cancer treatment outcomes. The research provides valuable insights into the mechanisms behind immunosuppression and tumor progression, ultimately aiming to improve the effectiveness of immunotherapy for cancer patients.

Summary

Glycyx, a biopharmaceutical company, highlighted a new publication in the Journal for ImmunoTherapy of Cancer that addresses opioid-induced immunotherapy failure. The study led by Dr. Nicole Scheff provides insights into how opioids impair immune checkpoint inhibitor efficacy, supporting the development of their lead candidate, axelopran.

Source Statement

This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Glycyx Sheds Light on Opioid-Induced Immunotherapy Failure in Cancer Treatment

blockchain registration record for the source press release.